Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The company will engage in investor meetings at the event, which is scheduled to take place in New York on Thursday, November 21, 2024.

News Market Reaction – LUNG

+1.09%

+1.09% Session move

In the trading session that priced this news, LUNG gained 1.09%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System, LungTraX^™ Platform, and StratX^® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

When is Pulmonx (LUNG) participating in the Canaccord Genuity Healthcare Forum?

Pulmonx (LUNG) will participate in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 21, 2024, in New York.

What type of event is Pulmonx (LUNG) attending in November 2024?

Pulmonx is attending the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, where they will participate in investor meetings.

Where will the Canaccord Genuity Forum featuring Pulmonx (LUNG) take place?

The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum will take place in New York.

What is Pulmonx's (LUNG) main business focus according to the announcement?

Pulmonx is described as a global leader in minimally invasive treatments for severe lung disease.